Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin monotherapy in advanced extrapulmonary neuroendocrine carcinoma or grade 3 neuroendocrine tumors
2024-515511-21-00Phase 2Authorised
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in neuroendocrine carcinoma (NEC) and apudoma (NET), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Objective response rate. Planned start Mar 2025; status: authorised.
02
Drugs
enfortumab vedotin
03
Conditions
neuroendocrine carcinoma (NEC)apudoma (NET)
Beyond the preview
Go deeper on 2024-515511-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515511-21-00.